The cumulative incidence of TKI stop eligibility after first line 2GTKI treatment was numerically higher than after imatinib treatment, but this did not reach statistical significance ( P =0.147) ( Figure 5B ).
← all excerpts
Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
1
0.1470
0.1470